Sign in by typing your Id and password
Settings
Help
Organizations >
BioVex Ltd
BioVex Ltd P07DC-THERA Partner |
BioVex is a Phase II clinical-stage biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Our pipeline of cancer product candidates is built on first-in-class oncolytic virus technology that replicates and spreads within solid tumors, causing the death of cancer cells, accompanied by the induction of a systemic immune response. We believe that this technology, "OncoVEX", is more effective than earlier-generation oncolytic viruses and has the potential to establish a new standard of care in the treatment of solid tumors, while minimizing side effects.
OncoVEXGM-CSF is completing a 50-patient Phase II clinical trial in the United States for the treatment of unresectable metastatic melanoma, as a monotherapy, in the second line/salvage therapy setting. Data so far indicates that OncoVEX can destroy both injected and un-injected melanoma deposits. Pivotal studies, intended for registration, are currently being planned.
Additional studies with OncoVEXGM-CSF are ongoing in head & neck cancer and pancreatic cancer.
Our lead infectious disease product candidate is ImmunoVEXHSV2 , a vaccine for genital herpes. At least 45 million people over the age of 11 in the United States have been infected with HSV-2, the cause of genital herpes. However, even though a number of HSV-2 vaccine candidates have previously been developed, none has proved broadly effective. ImmunoVEXHSV2 is a novel live-attenuated vaccine candidate that expresses approximately 80 HSV-2 proteins intended to stimulate a broad and powerful immune response. In preclinical studies, ImmunoVEXHSV2 completely prevents disease and invokes a powerful immune response, indicating that ImmunoVEX HSV2 is more potent than other HSV-2 vaccines for which published data are available. We intend to initiate a Phase I clinical trial for this product early in 2008.
OncoVEXGM-CSF is completing a 50-patient Phase II clinical trial in the United States for the treatment of unresectable metastatic melanoma, as a monotherapy, in the second line/salvage therapy setting. Data so far indicates that OncoVEX can destroy both injected and un-injected melanoma deposits. Pivotal studies, intended for registration, are currently being planned.
Additional studies with OncoVEXGM-CSF are ongoing in head & neck cancer and pancreatic cancer.
Our lead infectious disease product candidate is ImmunoVEXHSV2 , a vaccine for genital herpes. At least 45 million people over the age of 11 in the United States have been infected with HSV-2, the cause of genital herpes. However, even though a number of HSV-2 vaccine candidates have previously been developed, none has proved broadly effective. ImmunoVEXHSV2 is a novel live-attenuated vaccine candidate that expresses approximately 80 HSV-2 proteins intended to stimulate a broad and powerful immune response. In preclinical studies, ImmunoVEXHSV2 completely prevents disease and invokes a powerful immune response, indicating that ImmunoVEX HSV2 is more potent than other HSV-2 vaccines for which published data are available. We intend to initiate a Phase I clinical trial for this product early in 2008.
Affiliated Persons
|
|
Scientific responsible
|
|
|
|
|
Contact Information
| Phone |
+44 (0)1235 441900 | |
| Fax |
+44 (0)1235 441901 | |
| Web |
http://www.biovex.com/ | |
| Address |
70 Milton Park
OX14 4RX Abingdon Oxon United Kingdom |
|
]